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Carcinoid tumors are neoplasms that are seen in all portions of the gastrointestinal tract. In some instances, primary tumors can go undiagnosed or
misdiagnosed owing to nonspeciﬁc presenting symptoms. In this case report we discuss a patient with vague abdominal symptoms and radiographic
ﬁndings previously attributed to Crohn’s disease, who at operative exploration was found to have a metastatic carcinoid tumor. This report demonstrates
the nonspeciﬁc nature of metastatic carcinoid tumor and how its presentation can masquerade as more common gastrointestinal system abnormalities.
Copyright  2014, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Carcinoid tumors commonly originate in the gastrointestinal
tract and can present with vague abdominal symptoms and
nonspeciﬁc radiologic ﬁndings. Clinical diagnosis is difﬁcult, and
standard radiographic studies often miss the primary tumordthus,
diagnosis is often made after metastasis. Metastatic lesions are
associated with a lower 5-year survival rate, thereby increasing the
impetus for early diagnosis and intervention. This report highlights
the clinical challenges with carcinoid diagnosis and identiﬁes the
need for general practitioners, specialists, interventionalists, and
surgeons alike to consider alternative diagnosis when confronted
with intractable gastrointestinal complaints.
Occurring predominantly in the gastrointestinal tract and lung,
carcinoid tumors arise from neuroendocrine cells and are tradi-
tionally classiﬁed according to their embryologic site of origindthe
foregut, midgut, or hindgut. Foregut carcinoid tumors originate
most commonly in the lungs, bronchi, or stomach; midgut tumors
in the small intestine, appendix, or proximal large bowel; and
hindgut tumors in the distal colon and rectum. Each subgroup has
its own set of biologic and clinical characteristics.1Case report
A 57-year-old Caucasian female presented with cramping right
lower quadrant abdominal pain after meals and a 9-year history of
Crohn’s disease that was refractory to medical management. She
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in her course included adalimumab, azathioprine, and prednisone.
She had a number of previous operations including Nissen fundo-
plication with revision, appendectomy, cholecystectomy, hyster-
ectomy, and coronary bypass.
During the examination, she appeared healthy with stable vital
signs. Her abdomen was soft, without distention, but she had
diffuse tenderness without focal peritoneal signs. Laboratory ﬁnd-
ings included an albumin of 2.3 g/dL, C-reactive protein of 0.06 mg/
L, and erythrocyte sedimentation rate of 105 mm/h. Computed
tomography (CT) showed thickening of the cecum and terminal
ileum with mesenteric inﬂammation consistent with Crohn’s dis-
ease (Fig. 1). Small bowel follow-through showed no evidence of
stricture. At exploration, the distal ileum appeared ischemic, but a
strong pulse was felt in the superior mesenteric artery and ileocolic
artery. Around the terminal ileocolic artery, there was a ﬁbrotic,
contracted area of mesentery (Fig. 2). The involved segment was
resected as part of an ileocecectomy and primary anastomosis.
Pathological examination demonstrated a carcinoid tumor of
the small bowel, speciﬁcally a neuroendocrine tumor in the mes-
entery of the terminal ileum with local ﬁbrotic changes and bowel
ischemia. The tumor was determined to be a metastasis from an
unidentiﬁed primary site, and systemic therapy was initiated.2,3Discussion
Carcinoid tumors of the small bowel make up approximately
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Fig. 2. Operative image of contracted mesentery.
Fig. 1. Computed tomographic imaging axial view of the small bowel.
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frequently found in the distal ileum, are often multicentric, and
typically have a gross appearance of small, ﬁrm submucosal nod-
ules.2 They are commonly associated with both mesenteric nodal
disease and a local desmoplastic reaction to humoral agents elab-
orated by the tumor that can cause intermittent abdominal pain or
small-bowel obstruction. Routine radiological imaging, such as CTand contrast studies, rarely identiﬁes the primary tumor, so pa-
tients may have vague abdominal symptoms for years prior to the
diagnosis. As a result, the majority of patients with small-bowel
carcinoid present with metastases to the lymph nodes or liver.2
The treatment of small bowel carcinoid tumors is based on
tumor size, location, and the presence or absence of metastasis. For
small tumors (<1 cm) and no evidence of metastasis, a segmental
resection is recommended. For larger tumors, multiple tumors, or
regional lymph node metastasis, wide excision of the bowel and
mesentery is required.1 For widespread metastasis, surgery is still
indicated as debulking can provide symptomatic relief.1 Other
management options for clinically signiﬁcant progressive disease
include hepatic regional therapy (arterial embolization, chemo-
embolization, or radioembolization) or cytoreductive surgery
(ablative therapy).4 The goal of medical therapy is to relieve
symptoms from the excessive production of humoral factors.
Octreotide, a somatostatin analog, may decrease the secretory ac-
tivity of the carcinoid and may also have an antiproliferative effect.
The overall 5-year survival rate for carcinoid tumors (excluding
appendiceal) is approximately 90% but approaches 100% for non-
metastatic disease resected from the primary site. The 5-year sur-
vival rates for patients with regional disease and those with distant
metastasis are 65% and 25–35%, respectively.1 Early diagnosis and
surgery are thus imperative. The lack of speciﬁc radiological ﬁnd-
ings make early diagnosis a challenge, so a high level of clinical
suspicion in the face of refractory symptoms is required to ﬁnd
localized disease before metastases occur.
In our patient, pathology did not reveal a primary tumor in the
resected ileum or right colon. Serum chromogranin A was within
normal values, and an octreotide scan did not indicate pathologic
activity. It is our hypothesis that the primary tumor was resected
during her previous appendectomy > 25 years earlier. Her clinical
presentation likely resulted from metastatic disease and had been
incorrectly interpreted as Crohn’s throughout her longstanding
preoperative course. Even with advanced imaging techniques,
metastatic carcinoid is difﬁcult to diagnosis. Our patient’s story is a
clinical reminder to consider alternative pathologies in the face of
refractory disease.
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